Hudson Bay Capital Management LP Chemo Centryx, Inc. Transaction History

Hudson Bay Capital Management LP

$21.9 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $166,275 - $388,500	-7,500 Reduced 11.54%	57,500 $2.97 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $153,600 - $275,100	10,000 Added 18.18%	65,000 $1.61 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $1.22 Million - $2.15 Million	55,000 New	55,000 $1.38 Million
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $1.29 Million - $2.84 Million	-70,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $789,482 - $1.19 Million	-59,900 Reduced 46.11%	70,000 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $1.25 Million - $6.61 Million	129,900 New	129,900 $1.74 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.